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A new class of inhibitors of the AraC 
family virulence regulator Vibrio 
cholerae ToxT
Anne K. Woodbrey1, Evans O. Onyango1, Maria Pellegrini1, Gabriela Kovacikova2, 
Ronald K. Taylor2, Gordon W. Gribble1 & F. Jon Kull1
Vibrio cholerae is responsible for the diarrheal disease cholera that infects millions of people worldwide. 
While vaccines protecting against cholera exist, and oral rehydration therapy is an effective treatment 
method, the disease will remain a global health threat until long-term solutions such as improved 
sanitation and access to clean water become widely available. Because of this, there is a pressing need 
for potent therapeutics that can either mitigate cholera symptoms, or act prophylactically to prevent 
the virulent effects of a cholera infection. Here we report the design, synthesis, and characterization of 
a set of compounds that bind and inhibit ToxT, the transcription factor that directly regulates the two 
primary V. cholerae virulence factors. Using the folded structure of the monounsaturated fatty acid 
observed in the X-ray structure of ToxT as a template, we designed ten novel compounds that inhibit 
the virulence cascade to a greater degree than any known inhibitor. Our findings provide a structural 
and functional basis for the development of viable antivirulence therapeutics that combat cholera and, 
potentially, other forms of bacterial pathogenic disease.
Enteric diarrheal disease continues to be a global health concern and is especially deadly to children in third 
world countries1,2. Ironically, the most effective method of treatment – water – is also responsible for transmis-
sion: while oral rehydration therapy is highly effective, contaminated water harbors the diarrheal bacteria and 
spreads infection1. Yet, despite the fact that access to clean water is a simple solution to diarrheal disease, parts of 
the world stricken by natural and civil disasters often see an upsurge in cholera cases, and outbreaks are frequent 
and ongoing. The emergence of drug resistant bacterial strains and the inevitability of natural disasters add to the 
complexity of the problem. There is, therefore, immediate need for effective therapeutics against enteric bacterial 
infections that do not lead to increased resistance and are simple to deploy, prompting the current study.
Gastrointestinal infection caused by the ingestion of contaminated food or water is the primary cause of 
enteric diarrheal disease. While many enteric bacteria are acid labile, pathogens that survive conditions in the 
stomach3–6 go on to produce virulence factors through a chain of transcriptional events initiated by environ-
mental stimuli. Production of these virulence factors, including toxins and adhesion factors, ultimately results 
in diarrhea and other hallmarks of pathogenicity7. In the case of Vibrio cholerae, colonization depends on the 
toxin-coregulated pilus (TCP), which aggregates V. cholerae bacteria and induces microcolony formation8. The 
bacteria then express cholera toxin (CT), an exotoxin internalized into the host epithelial cells that disrupts ion 
transport and results in secretion of water into the lumen of the intestine9,10. Regulation of TCP and CT, the pri-
mary virulence factors of V. cholerae, depends primarily on the transcriptional activator ToxT11, a member of the 
large AraC/XylS family12,13. ToxT directly activates TCP and CT expression and thus is commonly referred to as 
the master regulator of V. cholerae virulence14,15.
Investigation of the environmental factors influencing V. cholerae virulence, such as amino acids and pH, 
dates back to the 1980s16. It was later suggested that bile had an effect on the ToxR regulon17, and, more spe-
cifically, on ToxT-dependent expression of CT and TCP18. Since then, our understanding of such effects has 
expanded, as has the goal to identify and exploit specific mechanisms involving ToxT regulation. The inhibitory 
effects of bile on V. cholerae virulence were eventually attributed to its unsaturated fatty acid (UFA) components19. 
While these findings documented inhibition of ToxT-activated gene expression by UFAs, a direct link between 
ToxT and fatty acids was not revealed until the X-ray structure was solved20. The presence of cis-palmitoleate, a 
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sixteen carbon monounsaturated fatty acid, in a pocket within the regulatory domain of ToxT suggested a fatty 
acid-mediated mode of inhibition and that oleic acid, a major component of bile19, could be the natural ToxT 
inhibitor20. Subsequent studies have shown that additional UFAs, including linoleic and conjugated linoleic acid, 
also inhibit ToxT19–22. The small molecule virstatin has also been shown to inhibit ToxT activity by preventing 
dimerization23,24. However, the concentrations required to reduce colonization in the infant mouse model were 
relatively high, and it has been shown that virstatin is not effective against some non-O1/non-O139 V. cholerae 
strains23,25.
In order to develop a more potent ToxT inhibitor, we have taken a structure-based approach to design a set of 
compounds that inhibit the V. cholerae virulence cascade. In this study, we used the folded conformation of the 
UFA ligand as inspiration to design a general bicyclic compound that will serve as the template for increasingly 
effective ToxT inhibitors. Our goal is to synthesize and characterize chemical derivatives of this model compound 
in order to determine the critical chemical characteristics responsible for inhibition. We present evidence that our 
most potent small-molecule inhibitors inhibit expression of essential colonization genes at 50 nM concentrations. 
These compounds represent a set of potential drug therapeutics that we show to be the most effective inhibitors 
of ToxT-regulated virulence gene expression described to date.
Results
Rational design of small-molecule inhibitors. The X-ray structure of ToxT revealed a 16-carbon mon-
ounsaturated fatty acid cis-palmitoleate bound in a pocket within the N-terminal domain20,26, the homologous 
location as the arabinose-binding site within AraC27, a related protein for which the family is named. The fatty 
acid bridges the interface between the N-terminal dimerization domain and C-terminal DNA-binding domain of 
ToxT, suggesting a potential mechanism for fatty acid-mediated inhibition (Fig. 1). The long aliphatic chain abuts 
hydrophobic residues within the N-terminal domain and helices 9 and 10 of the C-terminal domain, occupying 
the bulk of the binding pocket. The anionic carboxylate of cis-palmitoleate forms salt bridges with C-terminal and 
N-terminal lysine residues, presumably locking ToxT in a “closed” conformation in which it is unable to dimer-
ize and/or bind DNA20. It has also been suggested that ToxT is protected from proteolysis while in this inactive 
form28. According to current models20, upon the release of the fatty acid, repulsive forces between the neighboring 
lysine residues drive the N- and C-terminal domains apart. This results in an “open” state, freeing the C-terminal 
domain to bind DNA and/or allowing the N-terminal domain to dimerize20. It has been suggested that this rear-
rangement may involve the flexible N-terminal loop between residues 108–11326. Therefore, ToxT is thought to 
exist in “closed” (inactive) and “open” (active) states20.
This model implies that conformational changes in the ligand-binding pocket and domain interface, 
resulting from the presence or absence of UFA, influences the DNA-binding domain and/or the dimerization 
domain. Thus, we hypothesize that the carboxylate head and hydrophobic tail of cis-palmitoleate responsible for 
inter-domain interactions is critical for ToxT inhibition, and maintaining fatty acid-like character is required for 
an effective V. cholerae anti-virulence drug. Using the bound conformation of cis-palmitoleate as a template, we 
have designed a set of small-molecule inhibitors with these general characteristics (Fig. 2). Our design utilizes 
a fused ring system that should rigidify the synthetic compounds and lead to tighter binding. In contrast to the 
natural ligand, which must assume a constrained fold in the binding pocket, our “pre-folded” bicyclic compounds 
have already overcome this entropic penalty. The initial set of compounds includes variations in both the length 
of the carboxylate chain and degree of saturation of the ring system (Supplementary Fig. S1). We expect further 
modifications like these may optimize our design and allow the compounds to bind more tightly to the ToxT 
effector-binding pocket. For example, the affinity of the compounds may be improved by reduction of the tetralin 
to the corresponding decalin, and/or replacing the methyl group with a larger substituent (i.e. ethyl or t-butyl).
Figure 1. The fatty acid-binding region of ToxT. The carboxylate head of cis-palmitoleate interacts with Lys31 
of the N-terminal regulatory domain and Lys230 of the C-terminal DNA-binding domain. The full structure of 
ToxT is shown in the inset (PDB 3GBG). Blue, N-terminal domain; grey, C-terminal domain; green, fatty acid.
www.nature.com/scientificreports/
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Synthesis of small-molecule inhibitors. The small-molecule inhibitors, whose overall structures resem-
ble compounds 3–5, were synthesized according to the scheme in Fig. 3. The five- and six-step syntheses of the 
naphthalene 3, 4 and tetralin 5 analogs, respectively, utilized the well-known Mizoroki-Heck reaction29. The 
“anchor” for the palladium-catalyzed C-C coupling was 1-bromo-8-methylnaphthalene (1), whose synthesis we 
have previously optimized30. Following the attachment of the carboxylic acid chain to the naphthalene ring and 
hydrolysis of the ester 2 (if necessary), controlled catalytic hydrogenation gave the various final products, with 
the reaction time corresponding to the level of saturation; hydrogenation of the double bond in the carboxy-
late chain of 3 occurred after ~30 minutes to yield 4, while prolonged hydrogenation (overnight) yielded 5. (See 
Supplementary Information for detailed synthetic procedures and Supplementary Fig. S1 for the structures of all 
ten synthesized compounds.)
Inhibitors prevent virulence factor expression and ToxT-DNA binding. Initial screening of the 
synthetic inhibitors in a V. cholerae classical biotype transcriptional fusion system (tcpA-lacZ) revealed marked 
inhibition of tcpA expression, as measured in a β -galactosidase reporter assay (Fig. 4a). All ten compounds inhib-
ited tcpA transcription significantly more than virstatin, a molecule known to inhibit expression of V. cholerae 
virulence factors23, whereas cis-palmitoleic and oleic acids had essentially no effect at these concentrations 
(Fig. 4a). At 5 μ M, the strongest inhibitors decreased tcpA-lacZ transcription levels to almost baseline (that of 
ΔToxT tcpA-lacZ), but did not affect the number of colony forming units (data not shown). Expression of TcpA 
by Western Blot provided further evidence for the potency of our inhibitors, as the degree of inhibition by each 
compound was consistent with that determined by the β -galactosidase assay (Fig. 4b). Similarly, compounds 4a, 
5a, 3b, and 4b completely abolished detectable autoagglutination of O395 cultures at 0.5 μ M, while virstatin did 
not (Fig. 4c). When cells are grown under inducing conditions, the production of TCP pili allows for the forma-
tion of microcolonies, clusters of bacterial cells that are tethered together and which form a pellet in the bacterial 
culture31,32. This process is dependent on production of the major pilin subunit TcpA31. Autoagglutination was 
inhibited by compounds 4a, 5a, 3b, and 4b even at concentrations as low as 50 nM (Fig. 4c), potentially via inhibi-
tion of pili formation. As with the β -gal assay, cis-palmitoleic and oleic fatty acids had no effect on tcpA transcrip-
tion or autoagglutination at these concentrations (Supplementary Fig. S2).
It has been shown that virstatin and UFAs act on ToxT directly by affecting its ability to dimerize and/or bind 
DNA20,33. To determine if our newly synthesized compounds acted in a similar manner, electrophoretic mobility 
shift assays (EMSAs) were performed using purified ToxT protein and a digoxigenin-labeled 84 base-pair seg-
ment of the tcpA promoter34. At 100 μ M, all ten compounds and virstatin prevented ToxT from binding DNA 
(Fig. 5a). As expected, the same concentration of ToxT did not shift a similar mutated probe (Fig. 5b). It is known 
from prior studies that ToxT is unable to bind this probe due to two point mutations in the tcpA promoter35. The 
compounds with greatest inhibition of tcpA expression as determined by the β -galactosidase assay were assessed 
further in order to determine the concentration threshold required for inhibition. Compounds 4a, 5a, 3b, and 4b 
inhibited DNA-binding more strongly than virstatin, as seen in the dose-response EMSA (Fig. 5c).
X-ray crystal structures of ToxT-inhibitor complexes and computational modeling. While it is 
clear the above compounds are effective inhibitors of ToxT, in order to better understand the molecular basis 
of inhibition and elucidate the specific residues and interactions necessary for binding, we used the computa-
tional docking program AutoDock36 to predict how the compounds bind to ToxT. No significant differences in 
the free energies of binding were predicted, although there were slight modifications to the orientation of the 
docked ligands (Supplementary Fig. S3). In order to test the validity of the AutoDock models, we solved the 
crystal structures of ToxT bound to two of the most promising compounds, 5a and 3b, to 2.3 Å and 2.0 Å, respec-
tively. Electron density was visible in the effector-binding pocket of both structures that could not accommodate 
Figure 2. Small-molecule inhibitors resemble folded fatty acids. General structure of the small-
molecule inhibitors (left) compared to the 2D representation of cis-palmitoleic acid (middle) and the bound 
conformation of cis-palmitoleate from the X-ray crystal structure (right).
Figure 3. Synthetic scheme. The general synthetic procedure uses Heck coupling, ester hydrolysis, and 
hydrogenation to give the various small-molecule inhibitors.
www.nature.com/scientificreports/
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palmitoleic, oleic, or palmitic acids, but clearly fit the synthetic inhibitors (Fig. 6a and Supplementary Fig. S4). The 
positions and conformations of the inhibitors bound to ToxT in the X-ray crystal structures were similar to those 
predicted by AutoDock (Fig. 6c), providing additional confidence in the accuracy of the computational models for 
compounds for which we did not solve the X-ray structures. In the two crystal structures and all of the AutoDock 
structures, the compounds bound similarly to cis-palmitoleic acid (Fig. 6b and Supplementary Fig. S3), with the 
position of the carboxylate varying by 0.02–0.87 Å, suggesting favorable electrostatic interactions between the 
carboxylate head groups and Lys31 and Lys230. It seems that the bound conformation is dictated primarily by 
these carboxylate-lysine interactions. Beyond this, the planarity of the compound is the only other obvious factor 
determining how the inhibitors bind ToxT. For the more planar naphthalene compounds, the aromatic rings sit 
towards the bottom of the pocket (Fig. 6b, left and Supplementary Fig. S3, top and middle rows). The less planar 
tetralin rings, in contrast, are rotated clockwise 90°, so the aromatic rings sit towards the left side of the pocket. In 
this orientation, the fatty acid chain traces the perimeter of the tetralin compound almost perfectly (Fig. 6b, right 
and Supplementary Fig. S3, bottom row).
Inhibitors bind ToxT more tightly than virstatin. Saturation transfer difference (STD) NMR37 was used 
to characterize the strength of ToxT-ligand binding interactions. Significant STD signal was observed for virsta-
tin, confirming it binds to ToxT. As shown in Fig. 7a, saturation is transferred to the aromatic protons of virstatin 
upon binding to the protein. The STD effect on the aliphatic protons of virstatin was not analyzed due to their 
spectral overlap with ToxT. Based on the STD spectra for the aromatic protons Ha,b and He,f, the KD of virstatin 
was determined to be 483 ± 109 μ M and 331 ± 65 μ M, respectively (Supplementary Fig. S5). The relative binding 
affinities of compounds 3b and 5a were determined by competition STD NMR experiments. The compounds 
were titrated into samples containing 20 μ M ToxT and 100 μ M virstatin, causing a significant decrease in the 
STD signals of virstatin (Fig. 7b,c). X-ray crystallography has confirmed the binding pocket of compounds 3b 
and 5a; the decrease in the STD signal of virstatin upon the addition of the competitors suggests virstatin binds 
in the same effector-binding pocket of ToxT. Of course, an allosteric effect is also possible, with virstatin binding 
Figure 4. Synthesized compounds inhibit tcpA expression and autoagglutination activities. (a) Relative 
β -galactosidase activity of tcpA-lacZ fusion construct in the presence of virstatin (vir.), the ten synthesized 
compounds, oleic acid (OA), or palmitoleic acid (POA) at concentrations of 5 μ M (blue) and 0.5 μ M (grey). 
Relative β -gal activity was calculated as a percentage of the untreated wild-type (WT) strain ± DMSO. Δ ToxT 
is calculated relative to WT. Other values are calculated relative to WT + DMSO. Error bars represent standard 
deviation where n is 4. The average β -galactosidase activity (in Miller Units) for the WT samples in the absence 
and presence of DMSO are 15808 ( ± 1120) and 15986 ( ± 495) where n is 5. (b) Western blot showing TcpA 
production in the corresponding lanes. Compounds were added to a final concentration of 5 μ M. Fatty acids 
were not tested. The non-specific band is a loading control. (c) Autoagglutination of O395 cultures grown in the 
presence of 0.5 μ M (top) and 0.05 μ M (bottom) compounds 4a, 5a, 3b, and 4b.
www.nature.com/scientificreports/
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elsewhere on ToxT and influencing ligand binding at the UFA pocket28. Based on the calculated KD of virstatin 
and the decrease in the STD signal, the calculated Ki values of 3b and 5a were 10 μ M and 31 μ M, respectively. 
Despite a suggested tendency for virstatin to bind non-specifically at high concentrations (see Methods), the 
relative magnitudes of these binding constants are consistent with the activity assays described above.
Conclusion and Perspectives. The search for a strategy to combat Vibrio cholerae infections has been an 
ongoing focus of research in the field. Bile, unsaturated fatty acids (UFAs), and the small molecule virstatin are 
among the natural and synthetic inhibitors of V. cholerae virulence and its transcriptional activator ToxT17–20,23. 
New targets for the master virulence regulator ToxT have recently been identified38, however many are additional 
fatty acids21,22. Others include theoretical inhibitors identified computationally39, and effectors of toxT transcrip-
tion that fail to inhibit colonization40. While unsaturated fatty acids are effective, V. cholerae virulence inhibitors, 
the number of UFAs is finite and the likelihood of identifying an UFA that is significantly more potent than the 
rest is low. Additionally, what can be learned about ToxT and the detailed mechanisms of virulence inhibition is 
limited if analyses do not look beyond a single class of natural products. Screening of large small-molecule librar-
ies has identified ToxT inhibitors such as virstatin23, as well as others yet to be validated experimentally39. While 
virstatin has been demonstrated to be effective at reducing the transcriptional activity of ToxT in vitro and in vivo, 
it has significant limitations. For example, high concentrations were needed to inhibit colonization of the infant 
mouse (3.5 mM virstatin in the inoculum and 17.65 mM virstatin boosts)23. Also, V. cholerae strains resistance to 
virstatin have been identified25. As it is thought that virstatin inhibits ToxT activity by preventing dimerization24, 
some non-O1/non-O139 V. cholerae strains that demonstrate a stronger ToxT dimerization capability have been 
shown to be virstatin resistant25.
Therefore, in order to inhibit the activity of ToxT, our approach in this work was to design small molecules 
based on the conformation of the ToxT ligand found in the X-ray crystal structure, cis-palmitoleic acid20,26. As 
predicted, these “pre-folded” small molecules bind much more tightly than UFAs, which show no activity at 
the tested concentrations. The compounds do not inhibit colony formation, and are therefore not bactericidal, 
but were shown to inhibit virulence gene production via β -galactosidase and autoagglutination assays, and 
ToxT-DNA binding via EMSAs. The compounds bind to the effector-binding pocket of ToxT as predicted by 
AutoDock and visualized by X-ray crystallography. Based on a calculated KD determined by STD NMR, the lead 
compounds have at least 10-fold stronger binding affinities than the best-known ToxT inhibitor, virstatin23,24.
STD NMR data indicate virstatin binds in the same ligand-binding pocket of ToxT, which can accommodate 
only one ligand at a time. As verified in the X-ray crystal structures of the ToxT-inhibitor complexes, our synthetic 
compounds bind in the effector-binding pocket, and UFA is no longer observed. Ligand binding, which occurs 
at the interface between N- and C-terminal domains, clearly inhibits protein-DNA binding (via the C-terminal 
domain) and may inhibit dimerization (via the N-terminal domain)33,41,42. We will test the effects of compound 
binding on ToxT dimerization in future studies.
Previously identified Vibrio cholerae inhibitors, including virstatin, were identified from large small-molecule 
libraries via high-throughput screening23,40. In contrast, we have successfully designed, synthesized, and begun 
Figure 5. Synthesized compounds inhibit ToxT-DNA binding interactions. (a) ToxT EMSA in the presence 
of virstatin and the compounds. All lanes contain a DIG labeled, 84-bp segment of the tcpA promoter. All lanes 
except lane 1 contain 0.78 μ M ToxT. The solvent (DMSO) does not inhibit DNA binding (lane 3). A 100 molar 
excess of the unlabeled “cold” DNA segment competes for binding (lane 4). The presence of 100 μ M virstatin 
(vir) or 100 μ M compounds inhibits DNA binding (lanes 5–15). (b) ToxT does not shift the negative control 
CJ2.6 DNA35, a mutated segment of the tcpA promoter which ToxT cannot bind. (c) ToxT EMSA in the presence 
of virstatin and four lead compounds. All lanes contain labeled DNA. Virstatin is tested at 100, 10, 1, and 0.1 μ 
M concentrations. Compounds 4a, 5a, 3b and 4b are each tested at 10, 1, and 0.1 μ M. The EMSAs shown are 
representative of three or more independent experiments.
www.nature.com/scientificreports/
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characterization of specific inhibitors of V. cholerae ToxT. Our structure-based approach to drug design has 
resulted not only in a set of small molecules that appear to be the most effective ToxT inhibitors to date, but gives 
us a general template for designing more potent virulence inhibitors; inherent to our design is potential for a wide 
degree of variation to improve activity, specificity, and/or bioavailability. These novel compounds, while maintain-
ing an overall folded fatty acid-like shape, have a more constrained conformation that results in tighter binding 
to ToxT, presumably due to a more favorable entropic contribution to the free energy of binding. Optimization of 
the degree of saturation of the rings – from aromatic to partially or completely reduced – should allow for better 
accommodation of the compounds in the non-planar binding pocket. Similarly, varying the length of the carbox-
ylate chain and the substituent groups at the 8 position (i.e. the methyl) could fine-tune solubility, hydrophobic 
interactions, and further strengthen binding affinities.
Figure 6. X-ray crystal structures of ToxT-inhibitor complexes reveal compounds bind in the fatty acid-
binding pocket. (a) Simulated annealing Fo – Fc omit maps of ToxT bound to compounds 3b (left) and 5a 
(right) contoured at 2.5 σ . (b) Overlay of crystal structures of ToxT bound to fatty acid with ToxT bound to 3b 
(left) and ToxT bound to 5a (right). (c) Overlay of crystal structures of ToxT bound to 3b (left) and ToxT bound 
to 5a (right) with the conformations predicted by AutoDock. Pale green, ToxT bound to fatty acid (dark green, 
PDB ID 3GBG); grey, ToxT bound to compounds 3b (blue, PDB ID 5SUX) and 5a (tan, PDB ID 5SUW); yellow, 
bound confirmation of compound 3b as predicted by AutoDock; dark blue, bound confirmation of compound 
5a as predicted by AutoDock.
www.nature.com/scientificreports/
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The findings presented here describe the design and synthesis of antivirulence compounds specifically targeted 
to inhibit ToxT, which can potentially serve as novel and effective therapeutics against cholera. Furthermore, as 
UFAs have been shown to also inhibit other members of the AraC family that regulate virulence gene produc-
tion43, we hypothesize these compounds may be effective at inhibiting virulence gene expression in a variety of 
bacterial pathogens, and we hope to expand their therapeutic potential in order to advance the treatment and 
prevention of additional enteric diarrheal diseases.
Methods
β-galactosidase Assays. Cultures of the V. cholerae O395 tcpA-lacZ (MBN135) and ΔToxT tcpA-lacZ 
(MBN142) fusion constructs44 were grown for 14 hours with shaking in virulence inducing conditions (LB media 
pH 6.5 at 30 °C)8,45. For testing inhibitors, the compounds or DMSO were added to a final concentration of 0.05–
50 μ M at the time cultures were inoculated. β -galactosidase activity was quantitatively measured according to 
Miller46.
Western Blot. Whole-cell extracts were assayed for total protein concentration using the Pierce BCA Protein 
Assay Kit (Thermo Scientific). Samples were subjected to SDS-PAGE on 16% Tris-Glycine gels (Invitrogen) and 
transferred to a nitrocellulose membrane using iBlot (Invitrogen). The membrane was blocked with 3% bovine 
serum albumin in TBST (1x Tris-buffered saline, 0.1% Tween), incubated with anti-TcpA antibody47, and washed 
in TBST. After incubation with horseradish peroxidase-conjugated secondary antibody (Bio-Rad), the membrane 
Figure 7. STD NMR verifies direct binding of virstatin to ToxT and competition for the effector-binding 
pocket between virstatin and compounds 5a and 3b. (a) 1H-NMR spectrum of virstatin alone (top) and in 
the presence of 20 μ M ToxT (middle). The corresponding STD-difference spectrum (bottom). (b,c) 1H-NMR 
spectrum of 100 μ M virstatin in the presence of 20 μ M ToxT (top) and with the addition of compound 3b  
(b, middle) or compound 5a (c, middle). Competition STD-difference spectrum showing the reduction in STD 
signal intensities of virstatin due to competitors 3b (b, bottom) and 5a (c, bottom). Structures of virstatin, 3b, 
and 5a with aromatic protons labeled shown to the right of each corresponding spectrum.
www.nature.com/scientificreports/
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was washed in TBS. Blots were visualized using the Pierce ECL detection system (Thermo Scientific) according 
to the manufacturer’s protocols.
Colony Formation Units Assay. Samples grown in the presence or absence of the compounds were serially 
diluted and plated on LB-agar plates. Plates were incubated overnight at 37 °C and CFUs were counted. CFUs of 
cultures grown in the presence of compounds were compared to that of the wild-type O395 culture.
Autoagglutination Assays. Cultures of the V. cholerae classical strain O395 and O395ΔtoxT were grown 
for 14 hours with shaking in inducing conditions (LB media pH 6.5 at 30 °C). The compounds or DMSO were 
added at the time cultures were inoculated. After 14 hours, cultures were placed at room temperature and 
observed immediately.
ToxT Expression and Purification. ToxT was expressed by autoinduction from toxT-intein/CBD (chitin 
binding domain) fusion construct transformed in BL21-CodonPlus (DE3)-RIL E. coli, as described previously20. 
Cells were harvested by centrifugation, resuspended in medium-salt column buffer (20 mM Tris, 1 mM EDTA, 
500 mM NaCl, pH 7.5), lysed via sonication, and clarified by centrifugation. Clarified supernatant was loaded 
onto a gravity flow column packed with chitin beads (New England Biolabs) equilibrated in column buffer. After 
elution of the supernatant, the column was washed with column buffer followed by low-salt buffer (20 mM Tris, 
1 mM EDTA, 200 mM NaCl, pH 7.5), and equilibrated with cleavage buffer (low-salt buffer with 100 mM dithi-
othreitol (DTT)). The column was placed at 4 °C for 16 hours to cleave the intein/CBD. ToxT-intein/CBD fusion 
protein that co-eluted with the cleaved ToxT was separated using a HiTrap sepharose packed fast flow cationic 
exchange column (GE) with the following gradient: 45% high-salt buffer (20 mM Tris, 1 mM EDTA, 1 M NaCl, 
pH 7.5) for 175 minutes at a flow rate of 0.4 ml/min.
Electrophoretic Mobility Shift Assays. An 84-bp tcpA promoter fragment was amplified from V. cholerae 
O395 chromosomal DNA by PCR using 5′ labeled digoxigenin (DIG) primers: DIG-TCP-5 (5′ TGTTTCTTTCA 
ATGCAAGTG) and DIG-TCP-6 (5′ CACAAAGTCACCTACAATTG). Purified ToxT protein was mixed with 
0.5 ng DIG-DNA in a binding buffer (10 mM Tris pH 7.5, 1 mM EDTA, 100 mM KCl, 5 mM MgCl2, 1 mM DTT, 
0.3 mg/ml BSA, 0.25 μ g poly [d(I-C)], and 10% glycerol). Compounds in DMSO were added to a final concentra-
tion of 0.1–100 μ M, using the same volume of DMSO as a control. To show specificity, 100-fold excess of specific 
unlabeled dsDNA (84-bp tcpA promoter fragment) was added to one reaction tube. Similarly, 0.5 ng non-specific 
labeled dsDNA (mutated tcpA promoter fragment CJ2.635) was added in place of specific DIG-DNA for another. 
Reactions were incubated for 15 min at 30 °C, loaded on a 5% polyacrylamide gel (1x Tris-Borate EDTA, pH 8), 
and subjected to electrophoresis in 0.75x TBE at 4 °C. The DNA was transferred onto a positively charged nylon 
membrane (Roche) by electroblotting using 0.5x TBE at 4 °C, probed with anti-DIG-AP antibody, and visualized 
by chemiluminescence (Roche).
Crystallization. ToxT was co-crystallized with the synthesized compounds in hanging drops containing 50% 
protein buffer (20 mM Tris, 1 mM EDTA, 320 mM NaCl, pH 7.5) and 50% reservoir solution (0.1 M MES pH 6.5 
and 15% (w/v) PEG 400). The compound was added to 1.47 mg/ml ToxT at a 20:1 molar excess, and the complex 
was incubated at 30 °C for 15 minutes before setting up drops. The cryoprotectant for ToxT crystals contained 
0.1 M MES pH 6.5, 18% (w/v) PEG 400, and 30% 1,4-butanediol or glycerol.
X-ray data collection, structure solution, and refinement. Data sets were collected remotely at beam 
line GM/CA-XSD 23-ID-B at the Advanced Light Source at Argonne National Laboratory. Diffraction data were 
indexed and integrated with X-ray Detector Software (XDS)48 and merged using Phenix49. Molecular replacement 
solutions were obtained with Phenix Phaser-MR50 using ToxT (PDB ID 3GBG) with PAM deleted from the PDB. 
The initial model was built via Phenix AutoBuild51. Ligands were built from their SMILES strings using Phenix 
eLBOW52. The corresponding CIF files were viewed and edited in Phenix REEL52. Ligands were manually placed 
into the electron density using Coot53,54 and visualized using Pymol55. Iterative model refinement was performed 
using Phenix and Coot. Molecules of MES buffer were positioned in a similar manner as the ligands. Data collec-
tion and refinement statistics are presented in Supplementary Table S1.
Molecular Docking. Computational screening was carried out using Autodock 4.0.136. The coordinates for 
the receptor were obtained from the Protein Data Bank (PDB ID 3GBG) and were modified to exclude the bound 
PAM. The ligands were prepared from their SMILES description in Chimera56. All ligands as well as CD_CE and 
CE_NZ of lysine residues 230 and 31 of the receptor were considered flexible. A grid box with 35 × 40 × 32 points 
and a grid point spacing of 0.375 Å (gridcenter 54.5 × 46.5 × 20) encompassed the known binding pocket. Each 
docking simulation involved 20 evaluations using the Lamarkian genetic algorithm.
STD NMR. Sample preparation. Virstatin was solubilized in DMSO-d6 and compounds 5a and 3b in DMSO, 
at working stock concentrations of 35.5 mM, 394 mM, and 50.5 mM, respectively. Purified ToxT in protein buffer 
(20 mM Tris, 1 mM EDTA, 320 mM NaCl, pH 7.5) was used at a final concentration of 20 μ M. All samples con-
tained 50 μ M 3-(Trimethylsilyl)-1-propanesulfonic acid sodium salt (TSP) as an internal standard and 5% D2O. 
All NMR experiments were carried out on a Bruker Avance 600 MHz or 700 MHz spectrometer equipped with a 
TCI cryogenic probe. Samples were stored at 4 °C prior to acquisition.
Determination of KD of virstatin. KD determination followed the protocol outlined by Angulo et al.57. For 
on-resonance spectra, the protein was saturated at 500 Hz or 583.33 Hz for the 600 MHz and 700 MHz NMR 
spectrometers, respectively, for 1–4 seconds utilizing a train of 50 ms Gaussian pulses. For off-resonance spectra, 
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the sample was irradiated at − 2000 Hz. The total relaxation delay was 7 seconds. Data acquisition consisted of 
128 scans and 32,768 points. The STD-effect was calculated by measuring the intensity of the virstatin aromatic 
proton peaks in the on- and off-resonance spectra:
=
−I I I
I
x100
(1)STD
SAT0
0
The STD amplification factor (ASTD) values for different protons were fitted by using37:
= −−
−A t A e( ) [1 ] (2)STD SAT STD MAX
k t( )SAT SAT
where ASTD = ISTD ligand excess.
The initial slopes STD-AF0 (the initial growth rates of the STD amplification factors, which correspond to ASTD 
at zero tSAT) are obtained from:
− = −STD AF A k (3)STD MAX SAT0
where ASTD-MAX is the maximal achievable ASTD (for a very long saturation time).
The KD of virstatin was calculated using Michaelis-Menten kinetics. The STD-AF0 was plotted as a function of 
the ligand concentration to construct the binding (Langmuir) isotherm:
α
=
+
− =
+
y B L
L K
representing STD AF L
L K
[ ]
[ ]
[ ]
[ ] (4)
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D
STD
D
0
We determined the binding affinity of virstatin for ToxT in a concentration range of 66.5 to 665 μ M, collecting 
data for 7 different concentrations of virstatin. At concentrations higher than 665 μ M, we observed a pertur-
bation of the STD-effect attributable to non-specific binding of virstatin. It has been previously observed that 
non-specific binding at high ligand concentrations and high ligand/protein ratios can interfere with STD experi-
ments, since the non-specific binding can contribute to the total STD-effect58,59. We therefore did not include data 
points higher than 665 μ M.
Competition studies between virstatin and compounds 5a and 3b. Virstatin was used as the STD indicator at 
a concentration of 100 μ M. Compounds 5a and 3b were added at concentrations of 20–200 μ M. STD spectra 
were obtained as above, with a saturation time of 3 seconds. The calculation of the competitive inhibition was as 
follows60:
=
−
+
K C K iK
i C K
( )
( ) (5)I
I D D
L D
where CI is the concentration of inhibitor with unknown KD (compound 5a or 3b), CL is the concentration of 
ligand with known KD (virstatin), KD is that of virstatin, and i is the inhibition expressed as a fraction: 
= +i
I
I
SAT ligand inhibitor
SAT ligand alone
.
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